These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15310454)

  • 1. Wip1-deficient mice are resistant to common cancer genes.
    Harrison M; Li J; Degenhardt Y; Hoey T; Powers S
    Trends Mol Med; 2004 Aug; 10(8):359-61. PubMed ID: 15310454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis.
    Demidov ON; Kek C; Shreeram S; Timofeev O; Fornace AJ; Appella E; Bulavin DV
    Oncogene; 2007 Apr; 26(17):2502-6. PubMed ID: 17016428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
    Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
    Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wip1 phosphatase in breast cancer.
    Emelyanov A; Bulavin DV
    Oncogene; 2015 Aug; 34(34):4429-38. PubMed ID: 25381821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wip1-dependent signaling pathways in health and diseases.
    Zhu YH; Bulavin DV
    Prog Mol Biol Transl Sci; 2012; 106():307-25. PubMed ID: 22340722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wip1 phosphatase modulates ATM-dependent signaling pathways.
    Shreeram S; Demidov ON; Hee WK; Yamaguchi H; Onishi N; Kek C; Timofeev ON; Dudgeon C; Fornace AJ; Anderson CW; Minami Y; Appella E; Bulavin DV
    Mol Cell; 2006 Sep; 23(5):757-64. PubMed ID: 16949371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis.
    Belova GI; Demidov ON; Fornace AJ; Bulavin DV
    Cancer Biol Ther; 2005 Oct; 4(10):1154-8. PubMed ID: 16258255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
    Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
    Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.
    Schito ML; Demidov ON; Saito S; Ashwell JD; Appella E
    J Immunol; 2006 Apr; 176(8):4818-25. PubMed ID: 16585576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.
    Liu Y; Xu J; Choi HH; Han C; Fang Y; Li Y; Van der Jeught K; Xu H; Zhang L; Frieden M; Wang L; Eyvani H; Sun Y; Zhao G; Zhang Y; Liu S; Wan J; Huang C; Ji G; Lu X; He X; Zhang X
    Nat Commun; 2018 Nov; 9(1):4718. PubMed ID: 30413718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
    Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
    Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control.
    Choi J; Nannenga B; Demidov ON; Bulavin DV; Cooney A; Brayton C; Zhang Y; Mbawuike IN; Bradley A; Appella E; Donehower LA
    Mol Cell Biol; 2002 Feb; 22(4):1094-105. PubMed ID: 11809801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WIP1 phosphatase at the crossroads of cancer and aging.
    Le Guezennec X; Bulavin DV
    Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
    Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
    Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of proto-oncogene Wip1 in breast cancer and its clinical significance].
    Yang DH; He JA; Li J; Ma WF; Hu XH; Xin SJ; Duan ZQ
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(8):519-22. PubMed ID: 20367961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.
    Yamaguchi H; Durell SR; Chatterjee DK; Anderson CW; Appella E
    Biochemistry; 2007 Nov; 46(44):12594-603. PubMed ID: 17939684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene.
    Choi J; Appella E; Donehower LA
    Genomics; 2000 Mar; 64(3):298-306. PubMed ID: 10756097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
    Fuku T; Semba S; Yutori H; Yokozaki H
    Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
    Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
    J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.